dc.contributor.author | Morris, MJ | |
dc.contributor.author | de Bono, J | |
dc.contributor.author | Nagarajah, J | |
dc.contributor.author | Sartor, O | |
dc.contributor.author | Wei, XX | |
dc.contributor.author | Nordquist, LT | |
dc.contributor.author | Koshkin, VS | |
dc.contributor.author | Chi, KN | |
dc.contributor.author | Krause, BJ | |
dc.contributor.author | Herrmann, K | |
dc.contributor.author | Rahbar, K | |
dc.contributor.author | Vickers, A | |
dc.contributor.author | Mirante, O | |
dc.contributor.author | Ghouse, R | |
dc.contributor.author | Fizazi, K | |
dc.contributor.author | Tagawa, ST | |
dc.coverage.spatial | United States | |
dc.date.accessioned | 2024-09-13T14:52:25Z | |
dc.date.available | 2024-09-13T14:52:25Z | |
dc.date.issued | 2024-06-21 | |
dc.identifier.citation | Cancer, 2024, | en_US |
dc.identifier.issn | 0008-543X | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/6389 | |
dc.identifier.eissn | 1097-0142 | |
dc.identifier.eissn | 1097-0142 | |
dc.identifier.doi | 10.1002/cncr.35438 | |
dc.identifier.doi | 10.1002/cncr.35438 | |
dc.description.abstract | BACKGROUND: [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) plus protocol-permitted standard of care (SOC) prolonged overall survival (OS) and radiographic progression-free survival (rPFS) versus SOC in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 VISION study, in addition to beneficial effects on symptomatic skeletal events (SSEs) and health-related quality of life (HRQOL). METHODS: Post hoc analyses used the full analysis set from the VISION study (N = 831) overall and by randomized treatment arm (177Lu-PSMA-617 plus SOC, n = 551; SOC, n = 280). Correlations were determined between OS and rPFS and between rPFS or OS and time to SSE or to worsening HRQOL (Functional Assessment of Cancer Therapy-Prostate [FACT-P] and 5-level EQ-5D [EQ-5D-5L]). Correlation analyses used an iterative multiple imputation copula-based approach (correlation coefficients [rho] of <0.3 were defined as weak, ≥0.3 and <0.5 as mild, ≥0.5 and <0.7 as moderate, and ≥0.7 as strong). RESULTS: In the overall population, rPFS correlated strongly with OS (rho, ≥0.7). Correlations between rPFS or OS and time to SSE without death were weak or mild. Time to worsening in the FACT-P total score and emotional and physical well-being domains correlated mildly or moderately with rPFS and moderately with OS. Correlation coefficients for time-to-worsening EQ-5D-5L scores were mild to moderate for both rPFS and OS. Correlation coefficients were similar between treatment arms. CONCLUSIONS: In this analysis of the VISION study, rPFS correlated strongly with OS but not with time to SSE or worsening HRQOL. These findings require further investigation. | |
dc.format | Print-Electronic | |
dc.language | eng | |
dc.language.iso | eng | en_US |
dc.publisher | WILEY | en_US |
dc.relation.ispartof | Cancer | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en_US |
dc.subject | 177Lu‐PSMA‐617 | |
dc.subject | health‐related quality of life (HRQOL) | |
dc.subject | metastatic castration‐resistant prostate cancer (mCRPC) | |
dc.subject | radiographic progression‐free survival (rPFS) | |
dc.title | Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: Analysis of the phase 3 VISION trial. | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2024-05-17 | |
dc.date.updated | 2024-09-13T14:50:45Z | |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | 10.1002/cncr.35438 | en_US |
rioxxterms.licenseref.startdate | 2024-06-21 | |
rioxxterms.type | Journal Article/Review | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/39031642 | |
pubs.organisational-group | ICR | |
pubs.organisational-group | ICR/Primary Group | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group | |
pubs.publication-status | Published online | |
pubs.publisher-url | http://dx.doi.org/10.1002/cncr.35438 | |
icr.researchteam | PrCa Targeted Therapy | en_US |
dc.contributor.icrauthor | De Bono, Johann | |
icr.provenance | Deposited by Mr Arek Surman on 2024-09-13. Deposit type is initial. No. of files: 1. Files: Cancer - 2024 - Morris - Correlation analyses of radiographic progression‐free survival with clinical and health‐related.pdf | |